The early stage Alzheimer’s pipeline moves beyond amyloid

Why companies converging on tau for Alzheimer’s say it’s not β amyloid all over again

What Alzheimer’s targets beyond amyloid the biopharma industry is pursuing

What Biogen is building in neurology

How to interpret CTAD data for Lilly, Biogen anti-amyloid mAbs in AD

Asceneuron plans to show power of tau in AD by first tackling Orphan tauopathy